Careers

Support

Improving Critical Care with ECMO Therapy

Improving Critical Care
With ECMO Therapy

All-in-One Cardiopulmonary Support for ECMO

We offer extracorporeal membrane oxygenation (ECMO) devices for patients experiencing cardiopulmonary failure. Based on a holistic understanding of human physiology, we developed extracorporeal life support (ECLS) technologies that can impact the survival of critically ill patients.

We provide a solution that combines cardiopulmonary and respiratory support on a single technological platform, the Novalung® System.

The Novalung System provides physiologic gas exchange (oxygenation and CO2 removal) of the patient's blood in adults with acute respiratory failure or acute cardiopulmonary failure, where other available treatment options have failed, and continued clinical deterioration is expected or the risk of death is imminent.

ECMO thus provides physicians with crucial time for diagnosis and therapy.

Potential benefits of ECMO Therapy

Reduces the Need for Intubation

Prevents complications and reduces the risk of hospital-acquired infections1

Improves Survival for Patients in Cardiac Arrest

Has demonstrated survival rates 6 times higher than standard treatment4,5

Minimizes Invasive Ventilation

Prevents complications due to sedation and eliminates the trauma and discomfort to patients1

Impacts Post Operative Recovery

Reduces post operative recovery time due to reduced need for intubation and ventilation6

Allows Mobilization

Can be deployed where it is needed most in hospitals, including ICUs, operating rooms, emergency rooms, and cardiac catheterization labs2

Supports Complex Interventions

Allows surgical or medical correction of underlying pathology or injuries7,8

Enables Spontaneous Breathing

Leads to higher cardiac output and oxygen delivery3

Limits the Extent of Multi Organ Injuries

Prevents possible injury to the lungs due to intubation and ventilation8

Therapeutic Applications

Veno-arterial ECMO

Veno-arterial (VA) ECMO provides cardiopulmonary support. Blood is withdrawn from the venous system, oxygen is added and CO2 is removed, and the blood is returned to the arterial system. VA ECMO augments mean arterial pressure.

ECMO-Assisted Cardiopulmonary Resuscitation

ECMO-assisted cardiopulmonary resuscitation (ECPR) is a potential rescue therapy for patients in refractory cardiac arrest. It utilizes the principles of VA ECMO to reestablish aortic pressurization, allowing for end-organ perfusion.

Veno-venous ECMO

Veno-venous (VV) ECMO provides solely respiratory support, with no direct hemodynamic support. Blood is withdrawn from the venous system, oxygen is added, and CO2 is removed and then returned back to the venous system. Oxygen delivery is dependent on the patient's native cardiac function.

Extracorporeal Carbon Dioxide Removal

Extracorporeal carbon dioxide removal (ECCO2R) provides lung support by allowing for removal of excess CO2 from the blood. At the lower blood flows used for the extracorporeal CO2 removal (ECCO2R), no significant blood oxygenation takes place.

Get to know the Novalung System for ECMO

Contact Us for More Information

References

  1. Kluge S, Braune SA, Engel M, et al. Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med. 2012;38(10):1632-1639. doi:10.1007/s00134-012-2649-2
  2. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25 pt A):2769-2778. doi:10.1016/j.jacc.2014.03.046
  3. MacLaren G, Combes A, Bartlett RH. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med. 2012;38(2):210-220. doi:10.1007/s00134-011-2439-2
  4. Shin TG, Choi JH, Jo IJ, et al. Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: a comparison with conventional cardiopulmonary resuscitation. Crit Care Med. 2011;39(1):1-7. doi:10.1097/CCM.0b013e3181feb339
  5. Alsoufi B, Al-Radi OO, Nazer RI, et al. Survival outcomes after rescue extracorporeal cardiopulmonary resuscitation in pediatric patients with refractory cardiac arrest. J Thorac Cardiovasc Surg. 2007;134(4):952-959.e2. doi:10.1016/j.jtcvs.2007.05.054
  6. Khorsandi M, Dougherty S, Bouamra O, et al. Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2017;12(1):55. doi:10.1186/s13019-017-0618-0
  7. Arlt M, Philipp A, Voelkel S, et al. Extracorporeal membrane oxygenation in severe trauma patients with bleeding shock. Resuscitation. 2010;81(7):804-809. doi:10.1016/j.resuscitation.2010.02.020
  8. Hughes R, Cipolla J, Thomas PG, Stawicki SP. Extracorporeal membrane oxygenation in traumatic injury: an overview of utility and indications. In: Firstenberg MS, ed. Extracorporeal Membrane Oxygenation – Advances in Therapy. IntechOpen Limited; 2016:chap 11. doi:10.5772/63434


INDICATIONS FOR USE

The Novalung System is indicated for long-term (>6 hours) respiratory/cardiopulmonary support that provides assisted extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient's blood in adults with acute respiratory failure or acute cardiopulmonary failure, where other available treatment options have failed, and continued clinical deterioration is expected or the risk of death is imminent. These may include:

  • Failure to wean from cardiopulmonary bypass following cardiac surgery in adult patients
  • ECMO-assisted cardiopulmonary resuscitation in adults


Caution: Federal (US) law restricts these devices to sale by or on the order of a physician.

Note: Read the Instructions for Use for safe and proper use of these devices. The Indications for Use for this device can be found at https://fmcna.com/products/indications-safety-and-warnings.

© 2024 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, Novalung, X-Lung, and x.ellence are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. 105688-03 Rev A 02/2024